Last $3.65 USD
Change Today +0.32 / 9.61%
Volume 273.4K
STXS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

stereotaxis inc (STXS) Snapshot

Open
$3.35
Previous Close
$3.33
Day High
$3.69
Day Low
$3.35
52 Week High
08/6/13 - $10.18
52 Week Low
07/10/13 - $1.14
Market Cap
70.5M
Average Volume 10 Days
487.7K
EPS TTM
$-1.40
Shares Outstanding
19.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STEREOTAXIS INC (STXS)

Related News

No related news articles were found.

stereotaxis inc (STXS) Related Businessweek News

No Related Businessweek News Found

stereotaxis inc (STXS) Details

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive Robotic Navigation System, which offer navigation and stability for the diagnostic and ablation devices that assist in delivery of ablations. The company also offers Odyssey solution, which provides integrated real-time information solution to manage, control, record, and share procedures across networks; acquires a real-time remote view of the lab capturing synchronized procedure data for the review of events during cases; enable physicians to access recorded cases and create snapshots following procedures for clinical reporting, auditing, and presenting; and enables physicians to establish a master archive of procedures performed in the lab. In addition, it provides disposables and other accessories, such as Cardiodrive or QuikCAS automated catheter advancement disposables for the advancement of electrophysiology catheters; CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters; and Titan and Pegasus coronary guide wires for cardiology procedures. Further, the company offers V-CAS catheter and V-CAS Deflect integrated catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. It has strategic alliances with Siemens AG Medical Solutions, Philips Medical Systems, and Biosense Webster, Inc. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

123 Employees
Last Reported Date: 03/27/14
Founded in 1990

stereotaxis inc (STXS) Top Compensated Officers

Senior Vice President of Marketing & Business...
Total Annual Compensation: $265.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $243.0K
Vice President of Human Resources
Total Annual Compensation: $180.0K
Advisor
Total Annual Compensation: $352.0K
Compensation as of Fiscal Year 2012.

stereotaxis inc (STXS) Key Developments

Stereotaxis, Inc. Expands Credit Facility with Silicon Valley Bank to $10 Million

Stereotaxis Inc. announced that it has entered into an amended credit agreement with Silicon Valley Bank that replaces its existing $3 million revolving facility with a $10 million revolving facility scheduled to mature on March 31, 2015.

Stereotaxis Inc. Auditor Raises 'Going Concern' Doubt

Stereotaxis Inc. filed its 10-K on Mar 27, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Stereotaxis Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Stereotaxis Inc. announced unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, total revenue was $9,068,026 against $12,204,909 for the same period a year ago. Operating loss was $2,424,138 against $880,401 for the same period a year ago. Net loss was $3,962,208 or $0.23 basic and diluted per share against $4,316,661 or $0.55 basic and diluted per share for the same period a year ago. Excluding mark to market warrant revaluation and amortization of convertible debt discount, the fourth quarter 2013 adjusted net loss would have been $3.3 million or $0.19 per share and the fourth quarter 2012 adjusted net loss would have been $2.3 million or $0.29 per share. In the fourth quarter cash burn was $1.4 million compared to $100,000 in the prior year quarter. For the year, total revenue was $38,031,081 against $46,562,434 for the same period a year ago. Operating loss was $8,840,474 against $10,626,262 for the same period a year ago. Net loss was $68,757,589 or $5.95 basic and diluted per share against $9,238,427 or $1.33 basic and diluted per share for the same period a year ago. The decline in revenue was primarily a result of performing more ES upgrades during the initial product rollout in 2012 as well as lower Odyssey sales in 2013 compared to 2012. Net loss includes $54 million of charges reported as other expense and interest expense related to the non-cash mark-to-market adjustment and amortization of convertible debt discount as a result of transactions with convertible note holders and other equity investors. Excluding these charges, the net loss would have been $14.9 million or $1.29 per share. This compares to 2012 net loss of $16.5 million or $2.38 per share when excluding a mark-to-market revaluation and amortization of convertible debt discount related to the May of 2012 financing. For the full year 2013 cash burn was $6.3 million, a 48% reduction from 2012 and the lowest annual reported cash burn since it went public.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STXS:US $3.65 USD +0.32

STXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $16.10 USD -0.09
Hansen Medical Inc $2.23 USD +0.02
InspireMD Inc $2.36 USD -0.032
LeMaitre Vascular Inc $7.99 USD -0.02
Synergetics USA Inc $3.37 USD +0.04
View Industry Companies
 

Industry Analysis

STXS

Industry Average

Valuation STXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEREOTAXIS INC, please visit www.stereotaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.